Product Pipeline - Overview
Mersana is advancing a pipeline of next-generation antibody-drug candidates with the potential to improve patient outcomes in multiple oncology indications. Our approach to developing novel drug candidates begins with identifying a clinical unmet need, and then engineering novel drug conjugates that incorporate our Fleximer® polymer and linker chemistries customized to reach the desired activity profile and to overcome clinical obstacles.
This approach is particularly well suited for antibody-drug conjugate (ADC) engineering, successfully exploiting both full-length monoclonal antibodies and antibody fragments. Mersana is developing a portfolio of next-generation ADCs with superior properties not found with current ADC technologies.